Banking and Capital Markets Executive & Board Executive Chairman
Mike Sullivan is an accomplished Banking and Capital Markets Executive with experience across the US and Australia.
He is an inspirational leader who brings together talented teams to drive material business advantage. He has an established track record of success supporting and advising growing companies and business owners.
Today, he leads a successful Corporate Advisory business supporting clients across diverse contexts and is an active investor in the life sciences sector in Australia and globally.
Previously, he worked for 20 years in financial services across wealth management, equity capital markets, corporate advisory, and banking. His two decades’ experience includes 11 years at National Australia Bank, 3 years at Ferris Baker Watts in the US.
Mike has a Bachelor of Business Administration from Loyola College in Baltimore, Maryland USA.
Entrepreneur and founder of HK Biotechnology & Board Director
Jian Sun is the Founder of Huikang Bio-Tech and Director of Huikang Group. He has a very persistent belief in the health industry and biotechnology, a forward-looking strategic vision, excellent operational capabilities, and rich management experience.
Over 20 years of operating and running Huikang Group, which continues to this day, Mr Sun has overseen 60 patents granted in China and abroad, more than 50 patents pending, and a number of awards for its research achievements with many of those commercialised in market, in China. At present, A$100,000,000 has been invested to create the Huikang Biotechnology Industrial Park equipped with international advanced scientific research and production equipment, covering R&D, manufacture and sale of new drugs, gene therapy, cosmetics and medical devices.
In 2005 Mr Sun started doing business in Australia, with Melbourne now the international headquarters for Huikang Group. Mr. Sun and Huikang Group are dedicated and committed biotechnology industry participants with a long-term view to being a key contributor of the global biotech industry to advance mankind.
Robin Chambers AO
Corporate Lawyer and Advisor & Board Director
Robin Chambers has a distinguished career as an international lawyer; his global perspective has resulted in leading edge experience on the negotiation and documentation of numerous joint ventures in Australia and overseas.
He is currently the co-founder and Senior Partner of an Australian law firm which has a leading China and international law practice and is Chairman of China House, which is a consultancy for capital introductions on cross border investments. He has advised a number of major Chinese state-owned enterprises on their investments in Australia over a 34-year period.
Previously he has been chairman and director of ASX listed companies, General Counsel on numerous projects, including many of the major resources projects developed in Australia, as well as on projects across Asia and other continents. Robin has been involved in developing a number of funds in Australia and overseas in areas such as tourism, resources and biotech. His involvement extends to projects in more than 30 countries.
Robin has law degrees in Australia (Melbourne University) and in the USA (Duke) and is a MAICD. He received a citation in the Australian Queen’s Birthday Honour List 2012 as an Officer (AO) in the General Division of the Order of Australia, for his distinguished service to Australia-China relations, particularly in the promotion of trade and investment relationships.
Senior Corporate Advisor & Board Director
Glenn Cross has spent his career working in life sciences progressing from the lab bench to senior executive positions. His strong executive experience combined with deep laboratory experience gives him a solid understanding of the Australian and global biotech sector.
Currently he is involved in capital markets and general investment activities in North America, Asia and Australia. He is the CEO of his own investment and advisory company Red Bluff Capital. He is also a non-executive director on the board of a number of biotechnology and medical device companies.
Previously he was the Chief Operating Officer and CEO of AusBiotech for over 13 years, and has over 40 years’ experience in the life sciences sector. Glenn has held senior executive roles in both multinational and Australian companies. His expertise covers general management, sales, marketing, finance, distribution and manufacturing in the life sciences market.
Glenn also has experience in human resources, product development and manufacturing.
Ms Newstead-Sinclair is a Chartered Accountant and Member of the Governance Institute of Australia at the Corporate Business Service Provider, Vistra Australia. Ms Newstead-Sinclair has been CFO and Company Secretary for a number of ASX listed and unlisted public and private companies in the biotechnology and healthcare sectors, including over 9 years as Senior Director of Finance, Legal & HR and Company Secretary for Cogstate Limited (ASX:CGS).